Tags

Type your tag names separated by a space and hit enter

Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
J Exp Clin Cancer Res. 2001 Jun; 20(2):247-52.JE

Abstract

The high level of plasminogen activator inhibitor 1 (PAI-1) in colorectal cancer predicts poor prognosis for patients. The insertion (5G)/deletion (4G) polymorphism (the 4G/5G polymorphism) and G-->A single base substitution (the G/A polymorphism) located at promoter of PAI-1 gene may have functional significance in regulation of its expression. In the present work the level of PAI-1, distribution of genotypes and frequency of alleles of the 4G/5G and G/A polymorphisms in samples of cancer tissue and normal mucosa as well as in blood were investigated. Blood, tumor and normal tissues were obtained from 40 patients with colorectal cancer. The 4G/5G and G/A polymorphism were determined by PCR amplification using the allele specific primers. The PAI-1 level was measured by enzyme linked immunosorbent assay (ELISA). The distribution of the genotypes of both polymorphisms did not differ significantly (p > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distributions and allele frequencies between blood, normal mucosa samples and cancer tissue. The 4G/5G and G/A polymorphisms were in linkage disequilibrium. The average level of PAI-1 in tumor samples was significantly (p < 0.05) higher than in normal tissue. The results obtained indicate that a higher level of PAI-1 can be associated with colorectal cancer. On the other hand, in colon cancer, the 4G/5G and G/A polymorphisms are not linked with elevated levels of PAI-1 and therefore may not be used to predict colon cancer prognosis.

Authors+Show Affiliations

Smolarz B
Dept. of Molecular Genetics, University of Lodz, Poland.
Blasiak J
No affiliation info available
Kulig A
No affiliation info available
Romanowicz-Makowska H
No affiliation info available
Dziki A
No affiliation info available
Ulanska J
No affiliation info available
Pander B
No affiliation info available
Szewczyk T
No affiliation info available

MeSH

AdultAgedBase SequenceColorectal NeoplasmsDNA PrimersFemaleGene FrequencyGenotypeHumansMaleMiddle AgedMolecular Sequence DataPlasminogen Activator Inhibitor 1Polymerase Chain ReactionPolymorphism, GeneticPrognosisPromoter Regions, Genetic

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11484982

Citation

Smolarz, B, et al. "Plasminogen Activator Inhibitor 1 (PAI-1) Levels and Gene Promoter Polymorphisms in Subjects With Colorectal Cancer." Journal of Experimental & Clinical Cancer Research : CR, vol. 20, no. 2, 2001, pp. 247-52.
Smolarz B, Blasiak J, Kulig A, et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res. 2001;20(2):247-52.
Smolarz, B., Blasiak, J., Kulig, A., Romanowicz-Makowska, H., Dziki, A., Ulanska, J., Pander, B., & Szewczyk, T. (2001). Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. Journal of Experimental & Clinical Cancer Research : CR, 20(2), 247-52.
Smolarz B, et al. Plasminogen Activator Inhibitor 1 (PAI-1) Levels and Gene Promoter Polymorphisms in Subjects With Colorectal Cancer. J Exp Clin Cancer Res. 2001;20(2):247-52. PubMed PMID: 11484982.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. AU - Smolarz,B, AU - Blasiak,J, AU - Kulig,A, AU - Romanowicz-Makowska,H, AU - Dziki,A, AU - Ulanska,J, AU - Pander,B, AU - Szewczyk,T, PY - 2001/8/4/pubmed PY - 2002/1/5/medline PY - 2001/8/4/entrez SP - 247 EP - 52 JF - Journal of experimental & clinical cancer research : CR JO - J Exp Clin Cancer Res VL - 20 IS - 2 N2 - The high level of plasminogen activator inhibitor 1 (PAI-1) in colorectal cancer predicts poor prognosis for patients. The insertion (5G)/deletion (4G) polymorphism (the 4G/5G polymorphism) and G-->A single base substitution (the G/A polymorphism) located at promoter of PAI-1 gene may have functional significance in regulation of its expression. In the present work the level of PAI-1, distribution of genotypes and frequency of alleles of the 4G/5G and G/A polymorphisms in samples of cancer tissue and normal mucosa as well as in blood were investigated. Blood, tumor and normal tissues were obtained from 40 patients with colorectal cancer. The 4G/5G and G/A polymorphism were determined by PCR amplification using the allele specific primers. The PAI-1 level was measured by enzyme linked immunosorbent assay (ELISA). The distribution of the genotypes of both polymorphisms did not differ significantly (p > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distributions and allele frequencies between blood, normal mucosa samples and cancer tissue. The 4G/5G and G/A polymorphisms were in linkage disequilibrium. The average level of PAI-1 in tumor samples was significantly (p < 0.05) higher than in normal tissue. The results obtained indicate that a higher level of PAI-1 can be associated with colorectal cancer. On the other hand, in colon cancer, the 4G/5G and G/A polymorphisms are not linked with elevated levels of PAI-1 and therefore may not be used to predict colon cancer prognosis. SN - 0392-9078 UR - https://www.unboundmedicine.com/medline/citation/11484982/Plasminogen_activator_inhibitor_1__PAI_1__levels_and_gene_promoter_polymorphisms_in_subjects_with_colorectal_cancer_ L2 - https://www.diseaseinfosearch.org/result/1746 DB - PRIME DP - Unbound Medicine ER -